Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,256 across all filing types
Latest filing 2025-09-02 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Disclosure of material issue
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges, notifying them about the surrender of a manufacturing license by AstraZeneca Pharma India Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which pertains to disclosure of material events. The content is an update or announcement about a regulatory or operational change, not a financial report, audit, or detailed management discussion. The document length is only 1260 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-09-02 English
Disclosure of material issue
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges, notifying them about the surrender of a manufacturing license by AstraZeneca Pharma India Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which pertains to disclosure of material events. The document is an intimation or announcement rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. The length is only 1260 characters, indicating it is a brief announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-09-02 English
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges, notifying them about the surrender of a manufacturing license by AstraZeneca Pharma India Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an update or announcement about a regulatory or operational change, not a financial report, audit, or detailed management discussion. The document length is only 1260 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-09-02 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges disclosing an ESG rating assigned by an external agency (Crisil ESG Ratings) based on publicly available information. It explicitly states it is a disclosure under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to material event disclosures. The document does not contain the ESG report itself, financial statements, or detailed analysis, but rather informs the exchanges about the ESG rating received. The document length is short (1655 characters), and it is an announcement of information rather than a full report. Therefore, it fits best under Environmental & Social Information (SR) as it relates to ESG rating disclosure, but since it is a brief disclosure letter and not a full ESG report, and given the regulatory context, it is more appropriate to classify it as a Regulatory Filing (RNS) which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-09-01 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges disclosing an ESG rating assigned by an external agency (Crisil ESG Ratings & Analytics Limited) based on publicly available information. It explicitly states it is a disclosure under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to material event disclosures. The document does not contain the ESG report itself, financial statements, or detailed analysis, but rather informs the exchanges about the ESG rating received. The document length is short (1655 characters), and it is an announcement of information rather than a full report. Therefore, it fits best under Environmental & Social Information (SR) as it relates to ESG rating disclosure, but since it is a brief regulatory disclosure letter and not a full ESG report, and given the regulatory context, it is more appropriate to classify it as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Confidence is high due to clear regulatory references and document content.
2025-09-01 English
Please find the enclosed intimation of the Company in relation to the captioned subject.
Regulatory Filings
2025-08-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.